An experimental muon source(EMuS) will be built at the China Spallation Neutron Source(CSNS). In phase I of CSNS, it has been decided that EMuS will provide a proton beam of 5 kW and 1.6 GeV to generate muon beams. A ...An experimental muon source(EMuS) will be built at the China Spallation Neutron Source(CSNS). In phase I of CSNS, it has been decided that EMuS will provide a proton beam of 5 kW and 1.6 GeV to generate muon beams. A 128-channel muon spin rotation/relaxation/resonance(μSR) spectrometer is proposed as a prototype surface muon spectrometer in a sub-branch of EMuS. The prototype spectrometer includes a detection system, sample environment, and supporting mechanics. The current design has two rings located at the forward and backward directions of the muon spin with 64 detectors per ring. The simulation shows that the highest asymmetry of approximately 0.28 is achieved by utilizing two 10-mm-thick brass degraders. To obtain the optimal asymmetry, the two-ring structure is updated to a four-ring structure with 32 segments in each ring. An asymmetry of 0.42 is obtained through the simulation, which is higher than that of all the current μSR spectrometers in the world.展开更多
目的分析冠状动脉病变患者血清微小RNA(miR)-128-3p,miRNA-126表达与Gensini积分的相关性。方法选取哈励逊国际和平医院心内科2020年6月~2022年接诊的60例冠状动脉病变患者展开回顾性研究,将其设为观察组;另选取该院同期接诊的60例非冠...目的分析冠状动脉病变患者血清微小RNA(miR)-128-3p,miRNA-126表达与Gensini积分的相关性。方法选取哈励逊国际和平医院心内科2020年6月~2022年接诊的60例冠状动脉病变患者展开回顾性研究,将其设为观察组;另选取该院同期接诊的60例非冠状动脉病变患者,将其设为对照组,检测、比较两组血清miR-128-3p,miR-126和Gensini积分;比较观察组中单支、双支、多支病变患者血清miR-128-3p,miR-126和Gensini积分;根据冠状动脉狭窄率分为Ⅰ度、Ⅱ度、Ⅲ度和Ⅳ度组,比较不同狭窄分级组血清miR-128-3p,miR-126和Gensini积分;根据Gensini积分分为轻度病变组和重度病变组,比较轻度病变组、重度病变组血清miR-128-3p,miR-126;Pearson分析血清miR-128-3p,miR-126与Gensini积分的相关性;绘制受试者工作(ROC)曲线,计算曲线下面积(AUC),分析血清miR-128-3p,miR-126联合检测对冠状动脉病变的预测效能。Logistic回归分析冠状动脉病变的影响因素。结果与对照组比较,观察组血清miR-128-3p(4.28±0.52 vs 2.61±0.36),Gensini积分(31.29±5.62分vs 6.16±1.04分)升高(t=21.678,34.058),血清miR-126(11.05±3.16 vs 19.62±5.14)降低(t=11.002),差异具有统计学意义(均P<0.05)。与双支病变、单支病变组比较,多支病变组血清miR-128-3p,Gensini积分升高(t=4.945,7.171;6.795,11.686),血清miR-126降低(t=3.104,5.033),差异具有统计学意义(均P<0.05)。与Ⅰ~Ⅱ级组比较,Ⅲ~Ⅳ级组血清miR-128-3p,Gensini积分升高(t=5.590,12.961),血清miR-126降低(t=6.021),差异具有统计学意义(均P<0.05)。与轻度病变组比较,重度病变组血清miR-128-3p升高(t=4.056),血清miR-126降低(t=4.806),差异具有统计学意义(均P<0.05)。血清miR-128-3p与Gensini积分呈正相关性(r=0.404,P<0.05),血清miR-126与Gensini积分呈负相关性(r=-0.393,P<0.05)。血清miR-128-3p,miR-126联合检测的AUC高于单一检测,差异具有统计学意义(Z=2.768,2.152,均P<0.05)。观察组吸烟、三酰甘油(TG)、血尿酸(UA)、纤维蛋白原(FIB)与对照组比较,差异具有统计学意义(t/χ^(2)=4.231~28.732,均P<0.05)。结论冠状动脉病变患者血清miR-128-3p呈高表达,血清miR-126呈低表达,与Gensini积分存在一定的相关性,血清miR-128-3p和miR-126联合检测可提高对冠状动脉病变的预测效能,且冠状动脉病变的发生与多种因素有关,应当引起临床重视。展开更多
目的:探讨微小RNA-128-3p及微小RNA-381-3p对于下肢动脉硬化闭塞症患者的预测价值及相关因素分析。方法:选取2024年2月至6月青岛市市立医院本部院区血管外科共72例下肢动脉硬化闭塞症患者纳入实验组;同时随机选取健康志愿者共36例纳入...目的:探讨微小RNA-128-3p及微小RNA-381-3p对于下肢动脉硬化闭塞症患者的预测价值及相关因素分析。方法:选取2024年2月至6月青岛市市立医院本部院区血管外科共72例下肢动脉硬化闭塞症患者纳入实验组;同时随机选取健康志愿者共36例纳入对照组。采用实时荧光定量聚合酶链式反应(qRT-PCR)法检测血清miRNA-128-3p及miRNA-381-3p水平,采用酶联免疫吸附测定(ELISA)法检测血清白细胞介素(IL)-6、IL-8、金属蛋白酶组织抑制因子-1 (TIMP-1)水平。结果:下肢动脉硬化患者血清miRNA-128-3p及miRNA-381-3p的表达水平相较于健康人群来说明显上升,差异有统计学意义(p 0.05)。miRNA-128-3p、miRNA-381-3p、白介素-6、白介素-8、TIMP-1均为下肢动脉硬化的危险因素(p Objective: To explore the predictive value of microRNA-128-3p and microRNA-381-3p for patients with lower extremity arteriosclerosis obliterans and analyze the related factors. Methods: A total of 72 patients with lower extremity arteriosclerosis obliterans from the Department of Vascular Surgery of the Main Campus of Qingdao Municipal Hospital from February to June 2024 were included in the experimental group;simultaneously, 36 healthy volunteers were randomly selected and included in the control group. The levels of serum miRNA-128-3p and miRNA-381-3p were detected by real-time fluorescence quantitative polymerase chain reaction (qRT-PCR), and the levels of serum interleukin (IL)-6, IL-8, and tissue inhibitor of metalloproteinase-1 (TIMP-1) were detected by enzyme-linked immunosorbent assay (ELISA). Results: The expression levels of miRNA-128-3p and miRNA-381-3p in the serum of patients with lower extremity arteriosclerosis were significantly higher than those in healthy individuals, with statistically significant differences (p 0.05). miRNA-128-3p, miRNA-381-3p, IL-6, IL-8, and TIMP-1 were all risk factors for lower extremity arteriosclerosis (p < 0.05), but they were not supported as predictive factors for disease progression. Conclusion: miRNA-128-3p and miRNA-381-3p can be used as specific biomarkers for predicting lower extremity arteriosclerosis.展开更多
Hepatocellular carcinoma(HCC)shows the highest morbidity among liver cancers which is characterized by genetic mutations in hepatocytes,leading to uncontrolled cell growth and proliferation.Current treatment include s...Hepatocellular carcinoma(HCC)shows the highest morbidity among liver cancers which is characterized by genetic mutations in hepatocytes,leading to uncontrolled cell growth and proliferation.Current treatment include surgery,chemotherapy and immunotherapy;however,chemotherapeutics,which focus on single-targeted drug therapy,are still associated with certain limitations and may affect the treatment outcomes.Natural products also show the anticancer effect of HCC and hypotoxicity,but overall low activity of natural products limits their further application.miRNAs canmodulate post-transcriptional functions of target genes.An increasing body of evidence has demonstrated that miRNAs are the key regulators in HCC by targeting different molecules in different signaling pathways.However,miRNAs are fragile and liable to catabolism by RNases in serum and other body fluids,and small molecules separated from natural products may have limited bioavailability.A chitosan based,targeted,sustained-release nanoparticle deliverymiR-128–3p agomir(NA-miR-128–3p)was developed in this work.This nanoparticle was prepared by pentasodium tripolyphosphate(TPP),chitosan hydrochloride and miR-128–3p agomir with target aptamer which was loaded into the chitosan nanoparticle by self-assembly.It can intervene in HCC progress by affecting AKT1 expression.Based on this,a novel,efficient,long-acting,multi-mechanism and low-dosage combination drug delivery strategy was proposed in thiswork and showed a prominent anti-tumor effect.NA-miR-128–3p combined with natural product Oroxin B significantly affected HCC progression by the interference with VEGF and PI3K-AKT pathways,better than using NA-miR-128–3p and Oroxin B alone.Taken together,this nanoparticle and combinative administration compensate for the shortcomings of the fragile RNA drugs and the low activity of natural products,with high prospects in HCC treatment.展开更多
基金supported by the National Natural Science Foundation of China(No.11527811)the Key Program of State Key Laboratory of Particle Detection and ElectronicsA part of the work performed in the UKRI ISIS Detector Group was sponsored by the China Scholarship Council
文摘An experimental muon source(EMuS) will be built at the China Spallation Neutron Source(CSNS). In phase I of CSNS, it has been decided that EMuS will provide a proton beam of 5 kW and 1.6 GeV to generate muon beams. A 128-channel muon spin rotation/relaxation/resonance(μSR) spectrometer is proposed as a prototype surface muon spectrometer in a sub-branch of EMuS. The prototype spectrometer includes a detection system, sample environment, and supporting mechanics. The current design has two rings located at the forward and backward directions of the muon spin with 64 detectors per ring. The simulation shows that the highest asymmetry of approximately 0.28 is achieved by utilizing two 10-mm-thick brass degraders. To obtain the optimal asymmetry, the two-ring structure is updated to a four-ring structure with 32 segments in each ring. An asymmetry of 0.42 is obtained through the simulation, which is higher than that of all the current μSR spectrometers in the world.
文摘目的分析冠状动脉病变患者血清微小RNA(miR)-128-3p,miRNA-126表达与Gensini积分的相关性。方法选取哈励逊国际和平医院心内科2020年6月~2022年接诊的60例冠状动脉病变患者展开回顾性研究,将其设为观察组;另选取该院同期接诊的60例非冠状动脉病变患者,将其设为对照组,检测、比较两组血清miR-128-3p,miR-126和Gensini积分;比较观察组中单支、双支、多支病变患者血清miR-128-3p,miR-126和Gensini积分;根据冠状动脉狭窄率分为Ⅰ度、Ⅱ度、Ⅲ度和Ⅳ度组,比较不同狭窄分级组血清miR-128-3p,miR-126和Gensini积分;根据Gensini积分分为轻度病变组和重度病变组,比较轻度病变组、重度病变组血清miR-128-3p,miR-126;Pearson分析血清miR-128-3p,miR-126与Gensini积分的相关性;绘制受试者工作(ROC)曲线,计算曲线下面积(AUC),分析血清miR-128-3p,miR-126联合检测对冠状动脉病变的预测效能。Logistic回归分析冠状动脉病变的影响因素。结果与对照组比较,观察组血清miR-128-3p(4.28±0.52 vs 2.61±0.36),Gensini积分(31.29±5.62分vs 6.16±1.04分)升高(t=21.678,34.058),血清miR-126(11.05±3.16 vs 19.62±5.14)降低(t=11.002),差异具有统计学意义(均P<0.05)。与双支病变、单支病变组比较,多支病变组血清miR-128-3p,Gensini积分升高(t=4.945,7.171;6.795,11.686),血清miR-126降低(t=3.104,5.033),差异具有统计学意义(均P<0.05)。与Ⅰ~Ⅱ级组比较,Ⅲ~Ⅳ级组血清miR-128-3p,Gensini积分升高(t=5.590,12.961),血清miR-126降低(t=6.021),差异具有统计学意义(均P<0.05)。与轻度病变组比较,重度病变组血清miR-128-3p升高(t=4.056),血清miR-126降低(t=4.806),差异具有统计学意义(均P<0.05)。血清miR-128-3p与Gensini积分呈正相关性(r=0.404,P<0.05),血清miR-126与Gensini积分呈负相关性(r=-0.393,P<0.05)。血清miR-128-3p,miR-126联合检测的AUC高于单一检测,差异具有统计学意义(Z=2.768,2.152,均P<0.05)。观察组吸烟、三酰甘油(TG)、血尿酸(UA)、纤维蛋白原(FIB)与对照组比较,差异具有统计学意义(t/χ^(2)=4.231~28.732,均P<0.05)。结论冠状动脉病变患者血清miR-128-3p呈高表达,血清miR-126呈低表达,与Gensini积分存在一定的相关性,血清miR-128-3p和miR-126联合检测可提高对冠状动脉病变的预测效能,且冠状动脉病变的发生与多种因素有关,应当引起临床重视。
文摘目的:探讨微小RNA-128-3p及微小RNA-381-3p对于下肢动脉硬化闭塞症患者的预测价值及相关因素分析。方法:选取2024年2月至6月青岛市市立医院本部院区血管外科共72例下肢动脉硬化闭塞症患者纳入实验组;同时随机选取健康志愿者共36例纳入对照组。采用实时荧光定量聚合酶链式反应(qRT-PCR)法检测血清miRNA-128-3p及miRNA-381-3p水平,采用酶联免疫吸附测定(ELISA)法检测血清白细胞介素(IL)-6、IL-8、金属蛋白酶组织抑制因子-1 (TIMP-1)水平。结果:下肢动脉硬化患者血清miRNA-128-3p及miRNA-381-3p的表达水平相较于健康人群来说明显上升,差异有统计学意义(p 0.05)。miRNA-128-3p、miRNA-381-3p、白介素-6、白介素-8、TIMP-1均为下肢动脉硬化的危险因素(p Objective: To explore the predictive value of microRNA-128-3p and microRNA-381-3p for patients with lower extremity arteriosclerosis obliterans and analyze the related factors. Methods: A total of 72 patients with lower extremity arteriosclerosis obliterans from the Department of Vascular Surgery of the Main Campus of Qingdao Municipal Hospital from February to June 2024 were included in the experimental group;simultaneously, 36 healthy volunteers were randomly selected and included in the control group. The levels of serum miRNA-128-3p and miRNA-381-3p were detected by real-time fluorescence quantitative polymerase chain reaction (qRT-PCR), and the levels of serum interleukin (IL)-6, IL-8, and tissue inhibitor of metalloproteinase-1 (TIMP-1) were detected by enzyme-linked immunosorbent assay (ELISA). Results: The expression levels of miRNA-128-3p and miRNA-381-3p in the serum of patients with lower extremity arteriosclerosis were significantly higher than those in healthy individuals, with statistically significant differences (p 0.05). miRNA-128-3p, miRNA-381-3p, IL-6, IL-8, and TIMP-1 were all risk factors for lower extremity arteriosclerosis (p < 0.05), but they were not supported as predictive factors for disease progression. Conclusion: miRNA-128-3p and miRNA-381-3p can be used as specific biomarkers for predicting lower extremity arteriosclerosis.
基金supported by the National Natural Science Foundation of China(Grant 82373828)the National Key Technologies R&D Program of China(2023YFD1400902).
文摘Hepatocellular carcinoma(HCC)shows the highest morbidity among liver cancers which is characterized by genetic mutations in hepatocytes,leading to uncontrolled cell growth and proliferation.Current treatment include surgery,chemotherapy and immunotherapy;however,chemotherapeutics,which focus on single-targeted drug therapy,are still associated with certain limitations and may affect the treatment outcomes.Natural products also show the anticancer effect of HCC and hypotoxicity,but overall low activity of natural products limits their further application.miRNAs canmodulate post-transcriptional functions of target genes.An increasing body of evidence has demonstrated that miRNAs are the key regulators in HCC by targeting different molecules in different signaling pathways.However,miRNAs are fragile and liable to catabolism by RNases in serum and other body fluids,and small molecules separated from natural products may have limited bioavailability.A chitosan based,targeted,sustained-release nanoparticle deliverymiR-128–3p agomir(NA-miR-128–3p)was developed in this work.This nanoparticle was prepared by pentasodium tripolyphosphate(TPP),chitosan hydrochloride and miR-128–3p agomir with target aptamer which was loaded into the chitosan nanoparticle by self-assembly.It can intervene in HCC progress by affecting AKT1 expression.Based on this,a novel,efficient,long-acting,multi-mechanism and low-dosage combination drug delivery strategy was proposed in thiswork and showed a prominent anti-tumor effect.NA-miR-128–3p combined with natural product Oroxin B significantly affected HCC progression by the interference with VEGF and PI3K-AKT pathways,better than using NA-miR-128–3p and Oroxin B alone.Taken together,this nanoparticle and combinative administration compensate for the shortcomings of the fragile RNA drugs and the low activity of natural products,with high prospects in HCC treatment.
